. This vaccine not only provides protection against serogroup C, but also against 3 additional strains that cause meningococcal disease (serogroups A, Y and W-135). The vaccine is licensed for use in Canada between the ages of 9 months and 55 years of age. ...
(SEC-RI-MALS)to accurately measure the molecular weight of thepolysaccharide-CRM197 conjugates in the quadrivalent conjugate vaccine against group ACYW135 Neisseria meningitides.Methods The refractive indices(dn / dc)values were determined for each of the four polysaccharide-CRM197 conjugatesusing an...